Pneumococcal Conjugate Vaccine (PCV20)
PREVNAR 20™ Supplier: Pfizer Canada ULC

INDICATIONS:

- Healthy infants and children 2-59 months of age to start or complete a pneumococcal vaccine series
- Individuals 2 months of age and older who are at increased risk of invasive pneumococcal disease (IPD) due to: [A]

  Medical conditions:
  - Active malignant neoplasm (including leukemia and lymphoma) [B]
  - Anatomic or functional asplenia (congenital or acquired) or splenic dysfunction, including sickle cell disease and other hemoglobinopathies [C]
  - Chronic cerebrospinal fluid (CSF) leak [D]
  - Chronic heart disease requiring regular medication/follow-up [D]
  - Chronic kidney disease [E]
  - Chronic liver disease including cirrhosis, biliary atresia, chronic hepatitis B or individuals who are anti-HCV positive [E]
  - Chronic lung disease, including asthma requiring acute medical care (e.g., emergency department visit, hospitalization, or treatments such as oral steroids) in the preceding 12 months and infants born prematurely with ongoing lung impairment [D]
  - Chronic neurological conditions that may impair clearance of oral secretions [D]
  - Cochlear implant (candidate or recipient) [D]
  - Congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell mediated) immunity, complement system (properdin or factor D deficiencies) or phagocytic functions [E]
  - Cystic fibrosis [D]
  - Diabetes mellitus [D]
  - Hematopoietic stem cell transplant (HSCT) recipient or Chimeric Antigen Receptor T-cell (CART) therapy recipient
  - Human Immunodeficiency Virus (HIV) infection [F]
  - Immunocompromising conditions or immunosuppressive therapy within the past 2 years, including use of long-term corticosteroids, chemotherapy, radiation therapy, and immunosuppressive biologics [E]
  - Solid organ or islet cell transplant (candidate or recipient) [C]

  Social, behavioural, and environmental factors:
  - People experiencing homelessness and those who are underhoused [D]
  - Residents of long-term care (LTC) homes or assisted living facilities [D]
  - Substance use disorders (e.g., alcohol, cocaine, and injection drug use, etc.) [D]
- Healthy individuals 65 years of age and older [D]

[A] For infants and children under 5 years of age at increased risk of IPD, see Part 4 – Biological Products, Completing a Pneumococcal Conjugate Vaccine Series.

[B] Individuals 18 years of age and older are eligible for PCV20 if not previously vaccinated with either PCV20 or PCV21, regardless of PPV23 vaccine history. For those under 18 years of age, see Part 2 - Immunization of Special Populations, Pediatric Oncology Clients who have Completed Treatment, Including Autologous HSCT.

[C] Individuals 5 years of age and older are eligible for PCV20 if not previously vaccinated with either PCV20 or PCV21, regardless of PPV23 vaccine history.

[D] Eligible for PCV20 if not previously vaccinated with PCV20, PCV21 or PPV23.

[E] Individuals 5 years of age and older are eligible for PCV20 if not previously vaccinated with PCV20, PCV21 or 2 doses of PPV23 provided 5 years apart.

[F] Individuals 5 years of age and older are eligible for PCV20 if not previously vaccinated with PCV20, PCV21 or PCV 13 and 2 doses of PPV23 provided 5 years apart.

Pneumococcal Conjugate Vaccine (PCV20)
PREVNAR 20™ Supplier: Pfizer Canada ULC

INDICATIONS (continued):

RECOMMENDED BY THE NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION BUT NOT PROVIDED FREE IN BC:

- Smoking, particularly in those over 50 years of age
- Occupational risk with long-term continuous exposure to metal fumes (i.e., welders)
- Other individuals living in communities or settings experiencing sustained high IPD rates

---

DOSES AND SCHEDULE: [A]

Infants and children 2-59 months of age (inclusive): [B]

- Healthy infants and children: 3 doses given as 0.5 mL **IM** at 2, 4 and 12 months of age.
- Infants and children at increased risk of IPD: 4 doses given as 0.5 mL **IM** at 2, 4, 6 and 12 months of age.

Individuals 5 years of age and older at increased risk of IPD: 1 dose given as 0.5 mL **IM**.

Healthy adults 65 years of age and older: 1 dose given as 0.5 mL **IM**.

HSCT or CART therapy recipients: see Part 2 - Immunization of Special Populations, Hematopoietic Stem Cell Transplantation (HSCT) and Chimeric Antigen Receptor T-cell (CART) Therapy.

For those under 18 years of age with malignant neoplasm (including leukemia and lymphoma): see Part 2 - Immunization of Special Populations, Pediatric (those under 18 years of age) Oncology Clients who have Completed Treatment, Including Autologous HSCT.

ADMINISTRATION:

The product requires resuspension prior to administration. To re-suspend the vaccine, hold the pre-filled syringe horizontally between the thumb and the forefinger and shake vigorously until the contents of the syringe are a homogeneous white suspension. PCV20 should be stored horizontally in the refrigerator to minimize resuspension time. The vaccine can be used after it is resuspended to a homogenous white suspension. Do not use the vaccine if it cannot be re-suspended.

BOOSTER DOSES:

No booster doses are recommended at this time.

SEROLOGICAL TESTING:

Serological testing is not recommended before or after immunization.

[A] If PPV23 has already been administered, PCV20 should be administered one year later. See SPECIAL CONSIDERATIONS.

[B] Children who started a series with a lower valency PCV (e.g., PCV13, PCV15) should complete their series with PCV20 based on their age at presentation. Children who have previously completed an age-appropriate lower-valency PCV series are considered complete, with the exception of children at increased risk of IPD, see Part 4 – Biological Products, Completing a Pneumococcal Conjugate Vaccine Series for further guidance.

Pneumococcal Conjugate Vaccine (PCV20)
PREVNAR 20™ Supplier: Pfizer Canada ULC

CONTRAINDICATIONS:
1. History of an anaphylactic reaction to a previous dose of any pneumococcal vaccine or to any component of PREVNAR 20™.

PRODUCT COMPONENTS:
Potential allergens: diphtheria CRM_{197} toxoid protein, polysorbate 80.
Other components: succinic acid, aluminum phosphate.

PRECAUTIONS:
Not applicable.

SPECIAL CONSIDERATIONS:
- Health Canada has approved PCV15 for individuals 6 weeks of age and older and PCV21 for individuals 18 years of age and older; however, these vaccines are not publicly funded in BC.
- While the recommended interval between PPV23 and a subsequent PCV is one year, an interval as short as 8 weeks may be considered in those who might be anticipating initiation of immunosuppressive treatments or who have diseases that might lead to immunodeficiency.
- If a series is interrupted due to IPD, continue the series once the individual has recovered. Previous IPD does not confer immunity or preclude immunization with pneumococcal conjugate vaccine.

ADVERSE EVENTS:
Local: pain, redness, swelling.
Systemic: fever (and rarely, febrile seizures in young children), fatigue, headache, muscle and joint pain. Infants and toddlers may also experience irritability, increased or decreased sleep, decreased appetite, vomiting, diarrhea, rash.